Abstract
Introduction: Non-alcoholic steatohepatitis (NASH) is a progressive form of non-alcoholic fatty liver disease (NAFLD). At present, the diagnostic gold standard for detecting NASH still relies upon an invasive pathological biopsy. There is therefore a need to identify non-invasive diagnostic markers. Oxidative stress mediates fatty liver progression to NASH. Imbalanced iron metabolism produces a large amount of reactive oxygen species (ROS). Ceruloplasmin is associated with oxidase and iron metabolism-related activities. The current study aimed to determine whether there was a correlation between ceruloplasmin levels and NASH, and whether such a relationship may be associated with altered iron metabolism in NASH patients.
Materials and Methods: A total of 135 NAFLD patients were enrolled in this study, and a pathological biopsy confirmed that 60 of these patients had NAFLD activity scores (NAS) ≥ 5, while the remaining 75 had NAS < 5.
Results: Receiver operating characteristic (ROC) curves confirmed that serum ceruloplasmin and ferritin levels were predictors of NAS ≥ 5 and NAS < 5, with area under the curve (AUC) values of 0.80 and 0.81, respectively. The serum ceruloplasmin levels in NAS ≥ 5 patients were significantly lower than those in NAS < 5 patients (p < 0.001). Serum ceruloplasmin levels were also negatively correlated with ferritin levels, and lower serum ceruloplasmin levels were associated with more severe histopathological findings.
Conclusion: Low serum ceruloplasmin and high serum ferritin are correlated with NASH, and low serum ceruloplasmin may be associated with NASH owing to its ability to increase iron load.
Keywords
Array
Array
Array
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.